The machine learning model enhances transplant risk assessment for myelofibrosis by accurately identifying high-risk patients, outperforming traditional methods. A simplified 10-variable model ...

Optimal Jakafi dosing in myelofibrosis patients led to improved efficacy and manageable safety, with better spleen response rates and overall survival in the as-expected dosing group. The study ...

Disparities in mPDAC care quality and outcomes are linked to race and socioeconomic status, affecting cancer-specific survival. Socially vulnerable and minority patients are less likely to receive ...

As part of the agreement, VieCure will be making thousands of the most commonly used NCCN Chemotherapy Order Templates (NCCN Templates ®) available on the VieCure Halo Intelligence platform ...

"Although there are many models available to identify patients with high-risk myelofibrosis, we are still lacking tools to determine the risk of transplant for these patients," said one of the ...

Get Instant Summarized Text (Gist) A machine learning model developed by the European Society for Blood and Marrow Transplantation enhances transplant risk assessment for myelofibrosis patients ...

If your doctor thinks you may have myelofibrosis, several things will help with a diagnosis. There isn't just one test to check for the disease. Because every case is different, a physical exam ...

Presenting at the 2025 National Comprehensive Cancer Network (NCCN) Annual Meeting, Michael Kase, DMD, FAAMP, from University of Alabama at Birmingham School of Dentistry and the UAB O’Neal ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Jain ...

Instantly transforms textbooks, notes, and PDFs into optimized flashcards. Uses spaced repetition algorithms timed to combat forgetting. Extracts key concepts from lengthy chapters in seconds.

The NCCN Foundation has awarded over $11.7 million to 79 researchers through the YIA program since 2011, enabling studies that contribute to ongoing advances in cancer care.